Doron Ben-Meir

Director, Entrepreneurs’ Infrastructure Programme30 July 2014

The Future of Medical Research

Commercialisation

R&D (Invention)

Commercialisation

IPIP

$$

$$$$$$$$$$

The final value proposition for new IP is rarely clear at the outset

”

”

Supporting the commercialisation of novel intellectual property with commercial potential. It will provide access to appropriately skilled, experienced and independent Commercialisation Advisors, facilitate critical business connections through networking opportunities and offer targeted financial assistance.

Entrepreneurial Infrastructure

Funding Sources

Customers

Founders, Family and

Friends

Angels High Net-Worth

Strategic Corporates

Venture Capital Debt

Crowd Funding

Public Markets

Piecing it together

Western Australia3 Commercialisation Advisers

70 Participants

South Australia & the NT

3 Commercialisation Advisers37 SA + 3 NT Participants

Queensland 5 Commercialisation Advisers 151 Participants

New South Wales & ACT8 Commercialisation Advisers139 NSW Participants16 ACT Participants

Victoria & Tasmania6 Commercialisation Advisers134 VIC + 14 TAS Participants

Supporting a national portfolio of 500+ Companies and Researchers

A national network of Advisers

Growing Expert Network

As at July 2014

The Portfolio

As at July 2014

Biotechnology12%

Software & Web Design

34%

Computer Sys-tems

& Hardware12%

Manufacturing, Engineering &

Design42%

Value by key technology

Value by target market

As at July 2014

Agriculture and Food

Automotive, Aviation and Marine

Business and Communications

Defence, Security and Safety

Education and Training

Energy, Mining and Resources

Entertainment, Tourism and Sport

Health and Medical

Infrastructure and Building

OEM

Textiles, Clothing and Footwear

0 10000000 20000000 30000000 40000000 50000000 60000000

Endoluminal Pty Ltd

• Sydney medical technology company based on founders' research from Stanford & Sydney Universities

• Sealing technology for minimally invasive aortic valve replacement surgery - will prevent valve leakage which occurs in up to 50% of patients undergoing surgery

• Initial $227,500 grant

• License agreement with Swiss company Symetis SA in September 2013

Case Study

Admedus (formerly Celxcel Pty Ltd)

• Perth based biotechnology company

• Developed CardioCel®, a regenerative tissue product that treats and repairs congenital heart defects

• $1.9 million grant • In late 2013 Admedus raised

$10.4 million through a rights offer

• In February 2014 the US Federal Drug Administration approved the sale of CardioCel® in the US

Case Study

ElisaKit.com Pty Ltd

• Melbourne based biotech company

• Developed new process for the economic manufacture of ELISA (Enzyme-linked immunosorbent assay) kits that leverages innovative experimental design, statistical modelling and lean manufacturing

• Plan to market the kits in Australia and overseas

• $270,000 grant

Case Study

Global Kinetics Corporation Pty Ltd

Case Study

• Melbourne based medical technology company

• Developed Parkinson's KinetiGraph (PKG) System, a unique solution for neurologists in the management of Parkinson's disease symptoms

• PKG remotely records patient symptoms and reports this information to health professionals, allowing them to optimize drug performance

• The system also reminds the patient when to take their medication

• $400,000 grant

Nexvet Biopharma Pty Ltd

Case Study

• Melbourne based biotechnology company

• Developed a safe and effective therapeutic platform of biological drugs to treat dogs, cats and horses

• $300,000 grant• Raised $7 million in October 2013• In April 2014, Nexvet raised $31.5 million

from top-tier US-based investors including Farallon Capital Management, LLC, Adage Capital Partners, LP, Foresite Capital and Tavistock Life Sciences subsidiary fund, Boxer Capital.

PolyActiva Pty Ltd

• Melbourne biotech company • Developed a unique drug-polymer

technology for new biomedical products and device components, enabling drug delivery direct to organs

• $250,000 grant • Raised $9.2 million in a Series B

financing round from a consortium of investors including the Medical Research Commercialisation Fund, Brandon Capital, Yuuwa Capital and angel investors

Case Study

Contact Us

Web: www.Business.gov.auPhone: 13 28 46